Patrick Mcenany News Today

Key Insights Significantly high institutional ownership implies Catalyst Pharmaceuticals' stock price is sensitive to...

CORAL GABLES, Fla., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company, today announced that Patrick J. McEnany, Founder, Chairman and CEO of Catalyst, has been bestowed the 2023 Lifetime Achievement Award by BioFlorida at their Annual Meeting last Friday. This prestigious award highlights Mr. McEnany's outstanding accomplishments, unwavering commitment to rare diseas...

By Colin Kellaher Catalyst Pharmaceuticals co-founder Patrick McEnany, who has been at the helm of the drugmaker since its inception in early 2002, plans to...

Drug developer Santhera Pharmaceuticals agreed to the deal to license vamorolone to Catalyst for $75 million, plus an equity investment.

Catalyst Pharmaceuticals (CPRX) "hit the ball out of the park" in the first quarter, says Chief Executive Patrick McEnany. But CPRX stock fell after earnings…

Operator: Greetings and welcome to the Catalyst Pharmaceuticals first quarter 2023 financial results conference call. At this time, all participants are in a listen-only mode.

Catalyst's stock shot up after their sales for 2023 were forecasted to be higher than what analysts had originally predicted.

Greetings and welcome to the Catalyst Pharmaceuticals First Quarter 2021 Results Conference Call. [Operator Instructions] It is now my pleasure to introduce your host, Ms. Alicia Grande, Vice President, Chief Financial Officer and Treasurer. Thank you. You may begin. Alicia Grande -- Vice President, Chief Financial Officer and Treasurer Good morning, everyone, and thank you for joining our conference call to discuss Catalysts first quarter 2021 financial results and corporate highlights. Leadi...